Skip to content
JCP
PCC
News
CME
About
Authors
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
News
CME
About
Authors
Sign In
Subscribe
Clinical Topics
View All
Depression
Neurologic
Anxiety
Schizophrenia
Trauma
Psychopharmacology
Bipolar
Tardive Dyskinesia
OCD
Addiction
View All
Columns
View All
ASCP Corner
Clinical & Practical Psychopharmacology
Rounds General Hospital
Academic Highlights
Banner Alzheimer’s Institute
Focus on Geriatric Psychiatry
Robert J. Temple, MD
JCP
Review Article
FDA Perspective on Pimavanserin
June 28, 2017
In 2016, pimavanserin became the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. This article describes the regulatory and clinical issues important to the FDA's...
Mitchell V. Mathis
,
Brendan M. Muoio
,
Paul Andreason
, et al
JCP
Consensus Statement
Regulatory and Scientific Issues in Studies to Evaluate Sexual Dysfunction in Antidepressant Drug Trials
August 26, 2015
Ni A. Khin
,
Phillip D. Kronstein
,
Peiling Yang
, et al
JCP
Review Article
Summary of Findings From the FDA Regulatory Science Forum on Measuring Sexual Dysfunction in Depression Trials
August 26, 2015
Phillip D. Kronstein
,
Eiji Ishida
,
Ni A. Khin
, et al
JCP
Perspective
The US Food and Drug Administration's Perspective on the New Antidepressant Vortioxetine
November 11, 2014
Jing Zhang
,
Mitchell V. Mathis
,
Jenn W. Sellers
, et al
JCP
Original Research
Vilazodone: Clinical Basis for the US Food and Drug Administration's Approval of a New Antidepressant
September 15, 2011
Thomas P. Laughren
,
Jogarao Gobburu
,
Robert J. Temple
, et al
